Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Hochheim Am Main – page 10

1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hochheim Am Main at a glance
1 444
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 444 trials in Hochheim Am Main

Open in trial search

Influenza+1

Recruiting

Study of the safety and immune response of gskvx000000077430 drug combination versus standard influenza vaccine in adults 18‑64 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVX000000077430
  • Sponsor:GlaxoSmithKline Biologicals

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORG-129
  • Sponsor:Agomab Spain S.L.U.

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Soquelitinib
  • Sponsor:Corvus Pharmaceuticals Inc.

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camoteskimab
  • Sponsor:Apollo Therapeutics Limited

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Hochheim Am Main

What the registry says about research in the country

01 Rare Genetic Disorders

Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.

  • Gaucher Disease TYPE 3 Treatment
  • Niemann-Pick Disease Management
  • Genetic Disease Therapies

Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.

02 Lysosomal Storage Disorders

Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.

  • Hunter Syndrome Treatment
  • Infantile-onset Pompe Disease
  • Late-onset Pompe Disease

Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.

03 Respiratory Diseases

Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.

  • RSV Prevention
  • Vaccine Development
  • Immune Response Studies

Investigation of revaccination strategies and long-term protection against respiratory infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.